By Brazil Stock Guide – Neurotech, a B3-owned analytics brand, launched on Tuesday (Dec. 2) a new indicator designed to monitor trends in abuse and fraud attempts across Brazil’s private health-insurance market. Created in partnership with the Institute for Supplementary Health Studies (IESS), the tool offers a month-by-month view of irregularities, capturing shifts rather than isolated snapshots.
The index began in July 2025 and aggregates macroeconomic data, reimbursement patterns, potential document inconsistencies and unusual behaviors from providers and professionals. The objective is to show whether attempted irregularities are rising or declining over time — a key point in a sector under persistent cost pressure.
Early Readings
Health plans spent more than R$ 276 billion on medical-care expenses in 2024, according to the National Supplementary Health Agency (ANS), the sector’s federal regulator. Against this backdrop, Neurotech and IESS say the new indicator helps insurers better focus prevention strategies.
In a note, Neurotech stated that earlier studies provided only “a snapshot” of losses from abuse and fraud, while the new indicator “shows how attempted deviations evolve over time.” According to the company, suspicious activity fell between July and October, including a 15% drop from September to October.
IESS, also in a written note, said that as more months are added to the historical series, “the readings become clearer and more useful for market oversight.”
Sector Dynamics
The shift toward digital processes in health care increases the need for monitoring, according to IESS, which described the indicator as “a barometer of whether anti-fraud efforts are being effective.” The institution noted that maintaining system integrity is “as important as maintaining efficiency.”
Neurotech added that it continues to offer additional tools aimed at reducing irregularities in reimbursements, prior authorizations, medical billing and other operational journeys.
Leave a Reply